VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Escherichia coli carAB mutant vaccine
Vaccine Information
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Turkey
  • carA gene engineering:
    • Type: Gene mutation
    • Description: This carAB mutant is from Escherichia coli (Kwaga et al., 1994).
    • Detailed Gene Information: Click Here.
  • carB gene engineering:
    • Type: Gene mutation
    • Description: This carAB mutant is from Escherichia coli (Kwaga et al., 1994).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Oral immunization
Host Response

Turkey Response

  • Persistence: A carAB mutant is attenuated in turkeys (Kwaga et al., 1994).
  • Efficacy: A carAB mutant induces significant protection in turkeys from challenge with wild type E. coli (Kwaga et al., 1994).
References
Kwaga et al., 1994: Kwaga JK, Allan BJ, van der Hurk JV, Seida H, Potter AA. A carAB mutant of avian pathogenic Escherichia coli serogroup O2 is attenuated and effective as a live oral vaccine against colibacillosis in turkeys. Infection and immunity. 1994; 62(9); 3766-3772. [PubMed: 8063392].